Skip to main content
You have permission to edit this article.
Edit
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Concert Pharmaceutic (NQ: CNCE )

4.210 +0.110 (+2.68%)
Streaming Delayed Price Updated: 4:00 PM EDT, May 24, 2022 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 561,866
Open 4.100
Bid (Size) 4.020 (1)
Ask (Size) 4.500 (23)
Prev. Close 4.100
Today's Range 3.930 - 4.550
52wk Range 2.570 - 5.110
Shares Outstanding 32,173,778
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
The Analyst Says 'Impressive Phase 3 Data Highlight Best-In-Class Opportunity' For Concert Pharma
 
Via Benzinga
Concert Pharma's CTP-543 Shows Clinical Efficacy Against Scalp Hair Loss
 
Via Benzinga

Performance

YTD
+24.56%
+24.56%
1 Month
+27.96%
+27.96%
3 Month
+30.75%
+30.75%
6 Month
+10.21%
+10.21%
1 Year
+5.78%
+5.78%

More News

Read More
Concert Pharmaceuticals Reports Positive Topline Results for First CTP-543 Phase 3 Clinical Trial in Alopecia Areata
From Concert Pharmaceuticals, Inc.
Via Business Wire
Mizuho Sees Relief For This Small-Cap Stock After Patent Legal Overhang Lifted
Via Benzinga
Concert Pharma: Q1 Earnings Insights
Via Benzinga
90 Biggest Movers From Yesterday
Via Benzinga
12 Health Care Stocks Moving In Thursday's Intraday Session
Via Benzinga
58 Stocks Moving In Thursday's Mid-Day Session
Via Benzinga
28 Stocks Moving in Thursday's Pre-Market Session
Via Benzinga
Concert Pharmaceuticals Reports First Quarter 2022 Financial Results
From Concert Pharmaceuticals, Inc.
Via Business Wire
Earnings Outlook For Concert Pharmaceuticals
Via Benzinga
Concert Pharma Earnings Conference Call Is Coming Up, Here's What You Need To Know
Via Benzinga
Concert Pharmaceuticals to Report First Quarter 2022 Results on May 5, 2022
From Concert Pharmaceuticals, Inc.
Via Business Wire
Big Pharma's Sanofi Enters Licencing Agreement With Private Psychedelics Company Terran
Via Benzinga
Concert Pharmaceuticals Earnings Perspective: Return On Capital Employed
Via Benzinga
Recap: Concert Pharmaceuticals Q4 Earnings
Via Benzinga
A Preview Of Concert Pharmaceuticals's Earnings
Via Benzinga
Concert Pharmaceuticals to Report Fourth Quarter 2021 Results on March 3, 2022
From Concert Pharmaceuticals, Inc.
Via Business Wire
The Daily Biotech Pulse: J&J Unit Announces Research Collaboration With Remix, Regencell Touts COVID Data, Decision Day For Agios
Via Benzinga
Earnings Scheduled For March 3, 2022
Via Benzinga
Concert Pharmaceuticals Completes Enrollment in THRIVE-AA2 Phase 3 Clinical Trial Evaluating CTP-543 for Alopecia Areata
From Concert Pharmaceuticals, Inc.
Via Business Wire
Concert Pharmaceuticals to Present at H.C. Wainwright BIOCONNECT Virtual Conference
From Concert Pharmaceuticals, Inc.
Via Business Wire
Concert Pharmaceuticals to Participate in Fireside Chat at Jefferies London Healthcare Conferences
From Concert Pharmaceuticals, Inc.
Via Business Wire
Concert Pharmaceuticals, inc (CNCE) Q3 2021 Earnings Call Transcript
Via The Motley Fool
Topics Earnings
Exposures Financial
How Bad Are Concert Pharmaceuticals's Earnings? | Return On Capital Employed
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.